Bali Muralidhar, Director at Reneo Pharmaceuticals, Inc. (RPHM), bought 94,548 shares at $9.03 ($845K) on 2021-06-21, disclosed to the SEC on 2021-06-23.
Open-market purchase of $845k RPHM by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.03 | 32,659 | $295K | 34.9% |
| 2 | $9.03 | 32,659 | $295K | 34.9% |
| 3 | $8.72 | 14,615 | $127K | 15.1% |
| 4 | $8.72 | 14,615 | $127K | 15.1% |
| Total | $8.93 avg | 94,548 | $845K | 100% |
| Filing → |
| RPHM | BUY | 2021-06-25 | $384K | — | Filing → |
| RPHM | BUY | 2021-06-10 | $315K | — | Filing → |
| RPHM | BUY | 2021-06-07 | $114K | — | Filing → |